Commercial Insight: HIV in the USA Increasing Choice, Flexibility and Competition

Introduction:

With a focus on the commercial environment within the HIV sector in the USA, this Analysis investigates key market characteristics and the strategies required to improve market conditions. Analysis of company portfolio strategies and product positioning provides the reader with knowledge of how company strategies result in varying levels of commercial returns. 

Scope:

* Detailed case studies featuring company portfolio, product development and launch strategies 

* US sales data for the top 10 HIV products along with forecasts to 2011 for the top 10 selling HIV drugs and classes 

* SWOT analyses of key HIV drugs are provided, along with 12-month event screens - providing detailed knowledge of events specific to each product 

Report Highlights:

Despite a predicted slow down in overall growth and key obstacles with regard to efficacy, diagnosis, resistance and compliance, Datamonitor predicts that the US HIV market will more than double by 2011 providing an additional $4.2 bn in revenue.  

The approval of Roche’s novel fusion inhibitor Fuzeon will change treatment strategies for late stage patients. The key barrier to use is its delivery method (subcutaneous) and high price. 

With the launch of BMS’ Reyataz and BI’s tipranavir, the PI drug class will be as large as the NRTI drug class in terms of number of therapeutics. This will shift the usage of HAART towards NRTI-sparing regimens. 

Reasons to Purchase:

* Understand the relationship between company product positioning strategies and HIV market characteristics 

* Gain insight to HIV portfolio strategies and factors that drive successful drug development and launch 

Publisher: Datamonitor Infectious Diseases Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Infectious_Diseases.html#a224